ZD4054: all 31 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCKCompletedNCT06269484Phase 2Results posted
• Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)TerminatedNCT05516498Phase 2Results posted
• Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)CompletedNCT04724837Phase 2Results posted
• ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate CancerTerminatedNCT01119118Phase 2Results posted
• ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian CancerTerminatedNCT00929162Phase 2Results posted
• ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer StudyCompletedNCT00745875Phase 2Results posted
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate CancerTerminatedNCT00626548Phase 3Results posted
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate CancerCompletedNCT00617669Phase 3Results posted
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone MetastasesCompletedNCT00554229Phase 3Results posted
• ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)CompletedNCT00090363Phase 2Results posted
• A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate CancerCompletedNCT00055471Phase 2Results posted
• A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without FoodCompletedNCT07404137Phase 1
• A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High ProteinuriaActive, not recruitingNCT06942910Phase 2
• A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese ParticipantsCompletedNCT06715670Phase 1
• Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)Active, not recruitingNCT06087835Phase 3
• Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated AlbuminuriaCompletedNCT05570305Phase 2
• Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.CompletedNCT05505162Phase 1
• A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal ImpairmentCompletedNCT05112419Phase 1
• Precision Medicine With Zibotentan in Microvascular AnginaCompletedNCT04097314Phase 2
• Zibotentan Better Renal Scleroderma Outcome StudyCompletedNCT02047708Phase 2
• Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent ClaudicationCompletedNCT01890135Phase 2
• Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal CancerCompletedNCT01205711Phase 2
• Window Study of ZD4054 in Metastatic Prostate CancerStatus unknownNCT01168141Not applicable
• Carboplatin With or Without ZD4054 in Patients With Metastatic Breast CancerWithdrawnNCT01134497Phase 2
• A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate CancerTerminatedNCT01000948Phase 2
• 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid MalignanciesCompletedNCT00997945Phase 1
• Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.CompletedNCT00713791Phase 1
• Food Effect Study of a Single Dose of ZD4054 (Zibotentan)CompletedNCT00710047Phase 1
• Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)CompletedNCT00709553Phase 1
• Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic ImpairmentCompletedNCT00672581Phase 1
• Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPCCompletedNCT00314782Phase 1

← ZD4054 overview